Federated Hermes Inc. Lowers Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Federated Hermes Inc. lessened its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 10.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,364,666 shares of the biopharmaceutical company's stock after selling 1,264,059 shares during the quarter. Federated Hermes Inc. owned 8.79% of Dynavax Technologies worth $158,878,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Exchange Traded Concepts LLC lifted its holdings in shares of Dynavax Technologies by 1.5% in the 4th quarter. Exchange Traded Concepts LLC now owns 57,593 shares of the biopharmaceutical company's stock valued at $805,000 after buying an additional 828 shares during the period. Maryland State Retirement & Pension System lifted its holdings in shares of Dynavax Technologies by 1.9% in the 3rd quarter. Maryland State Retirement & Pension System now owns 47,440 shares of the biopharmaceutical company's stock valued at $701,000 after buying an additional 885 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in shares of Dynavax Technologies by 2.7% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 38,254 shares of the biopharmaceutical company's stock valued at $565,000 after buying an additional 1,000 shares during the period. State of Alaska Department of Revenue lifted its holdings in shares of Dynavax Technologies by 1.4% in the 3rd quarter. State of Alaska Department of Revenue now owns 79,735 shares of the biopharmaceutical company's stock valued at $1,177,000 after buying an additional 1,111 shares during the period. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Dynavax Technologies by 2.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 52,723 shares of the biopharmaceutical company's stock valued at $681,000 after buying an additional 1,442 shares during the period. Hedge funds and other institutional investors own 96.96% of the company's stock.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock traded down $0.09 during mid-day trading on Thursday, reaching $11.34. 2,181,391 shares of the stock traded hands, compared to its average volume of 1,948,096. The business has a 50-day moving average of $12.38 and a 200 day moving average of $13.33. Dynavax Technologies Co. has a fifty-two week low of $10.06 and a fifty-two week high of $15.15. The stock has a market capitalization of $1.48 billion, a PE ratio of -188.30 and a beta of 1.26. The company has a quick ratio of 12.96, a current ratio of 13.81 and a debt-to-equity ratio of 0.41.

Analyst Ratings Changes

A number of research firms recently weighed in on DVAX. StockNews.com cut Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Wednesday. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 23rd. Finally, The Goldman Sachs Group began coverage on Dynavax Technologies in a report on Thursday, February 1st. They issued a "neutral" rating and a $20.00 price target for the company. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Dynavax Technologies currently has an average rating of "Moderate Buy" and a consensus target price of $25.00.

Insider Buying and Selling at Dynavax Technologies

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $12.78, for a total transaction of $262,322.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.62% of the company's stock.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.